

Study: Human senescent fibroblasts cause lung fibrosis in mice

July 31 2023



The secretome of senescent human lung fibroblasts as mediator of murine lung fibrosis. Credit: 2023 Hernandez-Gonzalez et al.

A new research paper was published on the cover of *Aging*, titled "Human senescent fibroblasts trigger progressive lung fibrosis in mice."



Cell senescence has recently emerged as a potentially relevant pathogenic mechanism in fibrosing interstitial lung diseases (f-ILDs), particularly in idiopathic pulmonary fibrosis. In a new study, researchers from Hospital Clinic Barcelona, The Barcelona Institute of Science and Technology (BIST), Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), University of Barcelona, Karolinska Institute, Catalan Institution for Research and Advanced Studies (ICREA), and Altos Labs hypothesized that senescent human fibroblasts may suffice to trigger a progressive fibrogenic reaction in the lung.

"Here we: (1) explored this hypothesis in vivo; (2) investigated the potential underlying biological mechanisms in vitro; and (3) studied the effects of one experimental senolytic compound (navitoclax) and two anti-fibrotic drugs currently used in the treatment of IPF in humans (nintedanib and pirfenidone), both in vivo and in vitro," state the authors.

To address this, senescent human lung fibroblasts, or their secretome (SASP), were instilled into the lungs of immunodeficient mice. The researchers found that human senescent fibroblasts engraft in the lungs of immunodeficient mice and trigger progressive lung fibrosis associated to increasing levels of mouse senescent cells, whereas non-senescent fibroblasts do not trigger fibrosis.

They also found that the SASP of human senescent fibroblasts is prosenescence and pro-fibrotic both in vitro when added to mouse recipient cells and in vivo when delivered into the lungs of mice, whereas the conditioned medium (CM) from non-senescent fibroblasts lacks these activities. Finally, navitoclax, nintedanib and pirfenidone were found to ameliorate <u>lung</u> fibrosis induced by senescent human fibroblasts in mice, while only navitoclax displayed senolytic activity.



"We conclude that human senescent fibroblasts, through their bioactive secretome, trigger a progressive fibrogenic reaction in the lungs of immunodeficient mice that includes the induction of paracrine senescence in the cells of the host, supporting the concept that senescent cells actively contribute to disease progression in patients with f-ILDs," say the researchers.

More information: Fernanda Hernandez-Gonzalez et al, Human senescent fibroblasts trigger progressive lung fibrosis in mice, *Aging* (2023). DOI: 10.18632/aging.204825

Provided by Impact Journals LLC

Citation: Study: Human senescent fibroblasts cause lung fibrosis in mice (2023, July 31) retrieved 12 May 2024 from <u>https://medicalxpress.com/news/2023-07-human-senescent-fibroblasts-lung-fibrosis.html</u>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.